A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia

Status Completed

Clinical Trial Summary

Dyslipidemia contributes greatly to the formation and progression of atherosclerosis (AS), which plays a dominant role in leading to CHD.

Xuezhikang is a partially purified extract of fermented red yeast rice (Monascus purpureus). It is composed of 13 kinds of natural statins, unsaturated fatty acids, ergosterol,amino acids, flavonoids, alkaloid, trace element, and so forth. Xuezhikang has been recommended in a guideline for China adult dyslipidemia prevention.

This study aims to evaluate the benefit and side effect of Xuezhikang, a potential alternative drug of statins, for patients with dyslipidemia, and thus provide further evidence for clinical application.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02057302
Study type	Interventional
Source	China Academy of Chinese Medical Sciences
Contact
Status	Completed
Phase	Phase 4
Start date	March 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00001154` - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Not yet recruiting	`NCT06405880` - Pharmacist Case Finding and Intervention for Vascular Prevention Trial	N/A
Recruiting	`NCT02837367` - Use of Nutrigenomic Models for the Personalized Treatment With Medical Foods in Obese People	N/A
Active, not recruiting	`NCT02223793` - Vascular Lifestyle-Intervention and Screening in Pharmacy	N/A
Active, not recruiting	`NCT02600338` - Meta-analyses of the Effect of Legumes on Blood Pressure	N/A
Completed	`NCT02163044` - The Hellenic Postprandial Lipemia Study (HPLS)
Recruiting	`NCT01972113` - Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study)	N/A
Recruiting	`NCT01705873` - Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen	N/A
Completed	`NCT01764295` - Clinical Study for Patients With Hypertension Associated With Dyslipidemia	Phase 3
Terminated	`NCT01414166` - Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)	Phase 3
Completed	`NCT01531062` - Effect of Nigella Sativa on Lipid Profiles in Elderly	Phase 2
Completed	`NCT01990391` - Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities	N/A
Recruiting	`NCT01670968` - HIV Reverse Cholesterol Transport Study
Completed	`NCT00977288` - A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)	Phase 2
Completed	`NCT00768274` - Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol	Phase 1/Phase 2
Withdrawn	`NCT00664287` - Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)	Phase 3
Completed	`NCT01285544` - The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia	Phase 4
Completed	`NCT00300430` - Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.	Phase 3
Completed	`NCT01483235` - Reduced Cardiac Rehabilitation Program	N/A
Completed	`NCT00143663` - Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol	Phase 3